

# National Board of Examinations

<b>Question Paper Name :</b>	DrNB Medical Oncology Paper 3
<b>Subject Name :</b>	DrNB Medical Oncology Paper3
<b>Creation Date :</b>	2022-06-25 17:21:28
<b>Duration :</b>	180
<b>Share Answer Key With Delivery Engine :</b>	No
<b>Actual Answer Key :</b>	No

## DrNB Medical Oncology Paper 3

<b>Group Number :</b>	1
<b>Group Id :</b>	3271871115
<b>Group Maximum Duration :</b>	0
<b>Group Minimum Duration :</b>	180
<b>Show Attended Group? :</b>	No
<b>Edit Attended Group? :</b>	No
<b>Break time :</b>	0
<b>Group Marks :</b>	100
<b>Is this Group for Examiner? :</b>	No
<b>Examiner permission :</b>	Cant View
<b>Show Progress Bar? :</b>	No

## DrNB Medical Oncology Paper 3

<b>Section Id :</b>	3271871118
<b>Section Number :</b>	1

<b>Section type :</b>	Offline
<b>Mandatory or Optional :</b>	Mandatory
<b>Number of Questions to be attempted :</b>	10
<b>Section Marks :</b>	100
<b>Enable Mark as Answered Mark for Review and Clear Response :</b>	Yes
<b>Maximum Instruction Time :</b>	0
<b>Sub-Section Number :</b>	1
<b>Sub-Section Id :</b>	3271871122
<b>Question Shuffling Allowed :</b>	No

**Question Number : 1 Question Id : 32718710202 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Please write your answers in the answer booklet within the allotted pages as follows:-**

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

- Classify histiocytic disorders. [2]
- Clinical features and diagnosis of LCH. [4]
- Management of LCH. [4]

**Question Number : 2 Question Id : 32718710203 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

- What are adolescent and young adults (AYA) cancers? [2]
- Discuss the main issues related to AYA cancers in comparison to adult cancers. [4]
- Discuss the management of breast cancer in pregnancy. [4]

**Question Number : 3 Question Id : 32718710204 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

- a) Epidemiology and aetiology of gall bladder cancer in India. [4]
- b) Differences in the clinical presentation and biology of gall bladder cancer and cholangio-carcinoma. [4]
- c) Newer targets and therapies in the management of biliary cancers. [2]

**Question Number : 4 Question Id : 32718710205 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

- a) Define oligo metastatic disease in the context of breast cancer. [2]
- b) Role of surgery and radiotherapy in oligometastatic breast cancer. [4]
- c) Role of surgery in metastatic renal cell carcinoma. [4]

**Question Number : 5 Question Id : 32718710206 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

- a) WHO classification of acute myeloid leukaemia. [5]
- b) Management of elderly AML. [5]

**Question Number : 6 Question Id : 32718710207 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

- a) Discuss the pathology and molecular biology of rhabdomyosarcoma. [4]
- b) What are the favourable sites in rhabdomyosarcoma? [2]
- c) Role of radiotherapy in the management of Rhabdomyosarcoma. [4]

**Question Number : 7 Question Id : 32718710208 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

a) Pros and cons of short versus long course radiotherapy in rectal cancer. [5]

b) Discuss total neoadjuvant therapy in rectal cancer. [5]

**Question Number : 8 Question Id : 32718710209 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

a) Define endocrine resistance in breast cancer. [2]

b) Discuss the molecular mechanisms of endocrine resistance in breast cancer. (4)

c) Discuss the therapeutic agents available for management of endocrine resistance in breast cancer. [4]

**Question Number : 9 Question Id : 32718710210 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

a) Diagnosis and prognostication of chronic lymphocytic leukemia. [4]

b) Indications of treatment in CLL and discuss management strategy of CLL. [6]

**Question Number : 10 Question Id : 32718710211 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

a) Discuss CRISPR in relation to gene editing. [5]

b) Cytokine release syndrome in CART cell therapy and its management. [5]